Nocion Therapeutics Inc.

Chronic Cough Disorders

Nocion Therapeutics Inc. focuses on clinical research in refractory chronic cough and unexplained chronic cough, with attention to adult patients whose symptoms persist despite standard care.

  • Refractory chronic cough
  • Unexplained chronic cough
  • Persistent cough symptom control

The sponsor’s research activity is centered on therapeutic approaches intended to reduce cough burden and improve symptom management in a difficult-to-treat respiratory condition.

Respiratory Symptom Relief

The company’s trial portfolio reflects interest in treatments aimed at modifying cough frequency and addressing the sensory and functional impact of chronic respiratory symptoms.

  • Cough frequency reduction
  • Adult respiratory symptom management
  • Airway-related symptom burden

This area highlights a therapeutic emphasis on improving day-to-day respiratory comfort in patients with ongoing cough that lacks a clear or reversible cause.

Inhaled Therapeutics

Nocion Therapeutics Inc. is engaged in research involving inhaled treatment delivery for cough-related disease, reflecting interest in localized respiratory administration.

  • Inhalation powder
  • Pulmonary drug delivery
  • Respiratory-targeted therapy

The sponsor’s clinical work in this area aligns with therapeutic development for conditions affecting the upper and lower airways.

Adult Patient Population

The funded research is directed toward adults living with chronic cough, placing emphasis on symptom-focused care in a mature patient population.

  • Adult medicine
  • Symptom-focused respiratory care
  • Quality-of-life related cough outcomes

The clinical interest lies in conditions where cough persists as a primary complaint and remains a significant therapeutic challenge.

Respiratory Drug Development

As a pharmaceutical sponsor, Nocion Therapeutics Inc. is active in the development of novel therapies for chronic cough, with its clinical research concentrated on a single respiratory indication.

  • Novel cough therapeutics
  • Symptom-modifying respiratory medicines
  • Clinical respiratory innovation

Its research landscape is defined by a focused therapeutic interest in advancing options for patients with persistent cough disorders.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Study on the Effectiveness and Safety of Taplucainium Inhalation Powder (NOC-110) for Adults with Refractory or Unexplained Chronic Cough

    Not recruiting

    Investigated drugs:
    Belgium Germany Poland